Article Details
Retrieved on: 2025-06-20 19:05:08
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Genentech's trial yields a 59% reduction in disease progression for lymphoma patients. · Analysts forecast a potential 14.78% upside for Roche (RHHBY, ...
Article found on: www.gurufocus.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here